Evidence map›Paper›PMID 26066931›Full record

ArticleAmerican journal of public health2015

National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

Christopher M Jones, Melinda Campopiano, Grant Baldwin, Elinore McCance-Katz

3 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 340 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
340citing papers in PubMed, 7 pooled it
53.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02926482 nacompletednot on this mapstarted 2016, after this paper: background citation

Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2016 to 2019Enrolled76ConditionsOpioid-use DisorderArmsPrescriber Recruitment Bundle (PRB)
NCT03744663 phase2withdrawnnot on this mapstarted 2022, after this paper: background citation

A Randomized Pilot Study of Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films

TypeinterventionalSponsorWake Forest University Health SciencesRan2022 to 2022Enrolled0ConditionsOpioid UseArmsSuboxone® SL, Sublocade®
NCT04251208 completednot on this mapstarted 2019, after this paper: background citation

MOms in REcovery (MORE): Defining Optimal Care for Pregnant Women and Infants

TypeobservationalSponsorTrustees of Dartmouth CollegeRan2019 to 2024Enrolled444ConditionsOpioid-Related Disorders, NAS, Substance Use DisordersArmsObservational Study
3 · Its place in the literature

Who cites it

340 citing papers in PubMed, 7 syntheses or guidelines pooled it, 670 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2022
    Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Prescribers' satisfaction with delivering medications for opioid use disorder.Substance abuse treatment, prevention, and policy · 2021
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

280 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Christopher M JonesChristopher M. Jones is with the Office of Public Health Strategy and Analysis, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD. Melinda Campopiano is with the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD. Grant Baldwin is with the Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA. Elinore McCance-Katz is with the Office of Policy, Planning, and Innovation, Substance Abuse and Mental Health Services Administration.
Melinda CampopianoChristopher M. Jones is with the Office of Public Health Strategy and Analysis, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD. Melinda Campopiano is with the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD. Grant Baldwin is with the Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA. Elinore McCance-Katz is with the Office of Policy, Planning, and Innovation, Substance Abuse and Mental Health Services Administration.
Grant BaldwinChristopher M. Jones is with the Office of Public Health Strategy and Analysis, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD. Melinda Campopiano is with the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD. Grant Baldwin is with the Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA. Elinore McCance-Katz is with the Office of Policy, Planning, and Innovation, Substance Abuse and Mental Health Services Administration.
Elinore McCance-KatzChristopher M. Jones is with the Office of Public Health Strategy and Analysis, Office of the Commissioner, Food and Drug Administration, Silver Spring, MD. Melinda Campopiano is with the Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD. Grant Baldwin is with the Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA. Elinore McCance-Katz is with the Office of Policy, Planning, and Innovation, Substance Abuse and Mental Health Services Administration.
Substance Abuse and Mental Health Services Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions.

methodsWe generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more using Substance Abuse and Mental Health Services Administration data.

resultsNationally, in 2012, the rate of opioid abuse or dependence was 891.8 per 100 000 people aged 12 years or older compared with national rates of maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs of, respectively, 420.3 and 119.9. Among states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people. Thirty-eight states (77.6%) reported at least 75% of their OTPs were operating at 80% capacity or more.

conclusionsSignificant gaps between treatment need and capacity exist at the state and national levels. Strategies to increase the number of OA-MAT providers are needed.

Indexed as

Analgesics, OpioidBuprenorphineCapacity BuildingHealth Services Needs and DemandHealth SurveysHumansMethadoneOpiate Substitution TreatmentOpioid-Related DisordersUnited StatesAnalgesics, OpioidBuprenorphineMethadone

Identifiers

PMID26066931
PMCPMC4504312
OpenAlexW2164822993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.